IngredientsFlavin mononucleotide (FMN), or riboflavin-5′-phosphate, is a biomolecule produced from riboflavin (vitamin B2) by the enzyme riboflavin kinase and functions as the prosthetic group of various oxidoreductases, including NADH dehydrogenase, as well as a cofactor in biological blue-light photoreceptors. FMN is called a mononucleotide because it consists of the nitrogenous base flavin, the pentose alcohol ribitol, and a phosphate group. The molecule is sold under the brand name Epioxa and is also synonymously known as riboflavin-5′-monophosphate, riboflavin phosphate, sodium riboflavin phosphate (its sodium salt form), and vitamin B2 phosphate. It carries the CAS registry number 146-17-8 in its free-acid form. FMN requires more energy to produce than free riboflavin, but is more soluble in water.
FMN is the principal form in which riboflavin is found in cells and tissues. In cells, it occurs both freely circulating and in several covalently bound forms; covalently or non-covalently bound FMN is a cofactor of many enzymes playing an important pathophysiological role in cellular metabolism.
During the catalytic cycle, various oxidoreductases induce reversible interconversions between the oxidized (FMN), semiquinone (FMNH•), and reduced (FMNH₂) forms of the isoalloxazine core. FMN is a stronger oxidizing agent than NAD and is particularly useful because it can take part in both one- and two-electron transfers.
FAD and FMN cofactors are generated from riboflavin (vitamin B2), which can be synthesized de novo by plants, many bacteria and fungi, but not by animals, which must therefore obtain it from dietary sources. Riboflavin in foods is present predominantly in the form of FAD, with only small quantities available as FMN. Free riboflavin is naturally present in foods along with protein-bound FMN and FAD. Bovine milk contains mainly free riboflavin, with a minor contribution from FMN and FAD.
Foods that provide riboflavin without fortification include milk, cheese, eggs, leaf vegetables, liver, kidneys, legumes, mushrooms, and almonds. The major food sources of riboflavin are dairy products, especially milk, and meat and fish; most plants contain only small amounts of riboflavin. Over 90 percent of riboflavin is estimated to be in readily digested flavocoenzymes (mainly FAD and to a lesser degree FMN), with lesser amounts of the free vitamin and traces of glycosides and esters.
It is difficult to incorporate riboflavin into liquid products because it has poor solubility in water, hence the requirement for riboflavin-5′-phosphate (E101a), a more soluble form of riboflavin. Flavin mononucleotide is also used as an orange-red food colour additive, designated in Europe as E number E101a. Riboflavin-5′-Phosphate, designated as E101(ii), is the phosphorylated and water-soluble form of vitamin B₂ (riboflavin). It is widely used as a yellow to orange food coloring, as well as a bioavailable vitamin in functional foods, beverages, and supplements.
As a supplement, FMN is commercially available in several forms:
Riboflavin 5-phosphate is rapidly and almost completely dephosphorylated in the gastrointestinal lumen before absorption occurs. This means that when FMN is consumed orally, it is hydrolyzed back to free riboflavin prior to uptake — a pharmacokinetic consideration that is important for understanding whether supplemental FMN confers any bioavailability advantage over unphosphorylated riboflavin.
The industrial-scale production of riboflavin uses various microorganisms, including filamentous fungi such as Ashbya gossypii, Candida famata, and Candida flaveri, as well as the bacteria Corynebacterium ammoniagenes and Bacillus subtilis. B. subtilis that has been genetically modified to both increase the production of riboflavin and to introduce an antibiotic resistance marker is employed at commercial scale; by 2012, over 4,000 tonnes per annum were produced by such fermentation processes.
Unlike many botanical dietary supplements, FMN does not have a long history of intentional traditional or folk use as a distinct compound. Its history is inseparable from the scientific discovery of its precursor, riboflavin (vitamin B2), in the context of early 20th-century nutritional biochemistry.
The first observation of a pigment in milk with yellow-green fluorescence can be traced to the English chemist Alexander Wynter Blyth in 1872, but it was not until the early 1930s that the substance was characterized as riboflavin. Researchers realized that there were one or more additional water-soluble factors beyond thiamin, and these were called the vitamin B-2 complex. The search to identify these accessory food factors in milk, whole wheat, yeast, and liver began in the early 1900s.
Vitamin B2 (riboflavin) had been discovered in 1922 by Richard Kuhn in Germany and Theodor Wagner-Jauregg in Austria. The compound was isolated in 1933 by Kuhn and Paul György in Germany. The greenish yellow fluorescence of whey and egg white is caused by the presence of riboflavin, which was isolated in pure form in 1933 and was first synthesized in 1935. Kuhn also developed a synthetic route to riboflavin which was licensed to the German company I.G. Farben; meanwhile, in Switzerland, Hoffmann-LaRoche held patents for another method of synthesis from Paul Karrer.
The essential nature of riboflavin as an exogenous food constituent for the human organism was eventually proved by studies of William Henry Sebrell and Roy Edwin Butler in 1939. These workers reported that 13 out of 18 women who received a diet low in riboflavin developed a reddened, denuded lesion of the lips (cheilosis), maceration and fissuring of the angles of the mouth (angular stomatitis), and seborrheic accumulations at the nasolabial folds. Riboflavin was the second vitamin to be isolated and the first from the vitamin B-2 complex; the essential nature of the vitamin as a food constituent for man was shown in 1939.
As there is no classical nutritional disease attributable to riboflavin deficiency, it was the growth-stimulating properties of food extracts given to young rats that provided the tool with which to investigate and eventually extract riboflavin. FMN was subsequently identified and characterized as the active phosphorylated cofactor form of riboflavin through the mid-20th century biochemical work on flavoenzymes and the electron transport chain.
Because FMN exists as an endogenous biochemical intermediate — not as an isolated plant extract or herbal preparation — there is no recorded tradition of its deliberate use as a discrete therapeutic agent in historical herbalism or traditional medicine systems. What does exist is a centuries-long empirical understanding that certain foods (liver, milk, eggs, leafy greens) promoted vitality, growth, and recovery from mucosal ailments. These observations are now understood to reflect adequate riboflavin (and hence FMN and FAD) status, even though the molecular basis was unknown to the practitioners at the time.
Riboflavin is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As a pharmaceutical ingredient, FMN (usually in its sodium salt form) has been employed in injectable preparations for treating ariboflavinosis and deficiency states in clinical medicine in Europe and Asia since the mid-20th century.
Flavin mononucleotide (FMN) is formed first by the action of riboflavin kinase on riboflavin. FMN is then converted to flavin adenine dinucleotide (FAD) by the action of FAD synthetase. FMN and FAD are utilized as coenzymes in many biochemical reduction-oxidation reactions owing to the ability of the tricyclic isoalloxazine ring system to employ the oxidized, radical, and reduced state. The three oxidation states — FMN (oxidized), FMNH• (semiquinone radical), and FMNH₂ (fully reduced) — allow FMN to participate in both one-electron and two-electron transfer reactions, making it uniquely versatile among biological redox cofactors.
The flavin mononucleotide (FMN) cofactor of respiratory complex I occupies a key position in the electron transport chain. Here, the electrons coming from NADH start the sequence of oxidoreduction reactions, which drives the generation of the proton-motive force necessary for ATP synthesis.
All redox reactions take place in the hydrophilic domain of complex I. NADH initially binds to complex I, and transfers two electrons to the flavin mononucleotide (FMN) prosthetic group of the enzyme, creating FMNH₂. The electron acceptor — the isoalloxazine ring — of FMN is identical to that of FAD. The electrons are then transferred through the FMN via a series of iron-sulfur (Fe-S) clusters, and finally to coenzyme Q10 (ubiquinone).
Complex I, also known as ubiquinone oxidoreductase, is made up of NADH dehydrogenase, flavin mononucleotide (FMN), and eight iron-sulfur (Fe-S) clusters. The NADH donated from glycolysis and the citric acid cycle is oxidized here, transferring two electrons from NADH to FMN.
Conditions for the reversible dissociation of flavin mononucleotide (FMN) from the membrane-bound mitochondrial NADH:ubiquinone oxidoreductase (complex I) are well described. Dissociation of flavin mononucleotide from mitochondrial complex I has been shown to occur during ischemia/reperfusion brain injury during stroke. This represents a pathophysiologically significant mechanism by which disrupted FMN availability can impair cellular energy production in the context of acute tissue injury.
FMN (also known as riboflavin-5′-phosphate) and FAD are essential components of two major coenzymes. These coenzymes play major roles in energy production; cellular function, growth, and development; and metabolism of fats, drugs, and steroids.
Riboflavin-dependent enzymes include succinate dehydrogenase, NADH dehydrogenase, ferredoxin-NADP⁺ oxidoreductase, acyl-CoA dehydrogenase, and the pyruvate dehydrogenase complex. Consequently, fatty acid oxidation, the TCA cycle, mitochondrial electron transport, photosynthesis, and numerous other cellular processes are critically dependent on either FMN or FAD as prosthetic groups.
The conversion of vitamin B6 to the coenzyme pyridoxal 5′-phosphate requires FMN. The conversion of the amino acid tryptophan to niacin (vitamin B3) requires FAD. This means that adequate FMN and FAD availability is necessary not only for direct redox reactions but also for the functional activation of other B vitamins.
An enzyme involved in folate metabolism, 5,10-methylenetetrahydrofolate reductase (MTHFR), requires FAD to form the amino acid methionine from homocysteine. FAD contributes to the conversion of tryptophan to niacin (vitamin B3), and the conversion of vitamin B6 to the coenzyme pyridoxal 5′-phosphate requires FMN.
The flavin coenzymes support the function of roughly 70–80 flavoenzymes in humans (and hundreds more across all organisms, including those encoded by archaeal, bacterial, and fungal genomes) that are responsible for one- or two-electron redox reactions. Other notable flavoproteins include glutathione reductase, glycolate oxidase, P450 oxidoreductase, squalene epoxidase, dihydroorotate dehydrogenase, and α-glycerophosphate dehydrogenase.
Because of the many different roles of the flavoenzymes in intermediary metabolism, the important role of riboflavin (such as in antioxidant defense or in the modulation of homocysteine metabolism) is often forgotten.
In its role as a blue-light photoreceptor, oxidized FMN stands out from the 'conventional' photoreceptors as the signaling state and not an E/Z isomerization. This function underpins the signaling biology of phototropins and other light-oxygen-voltage (LOV) domain proteins in plants, fungi, and bacteria, which use FMN as the chromophore for blue-light sensing.
To be available for absorption, FAD and FMN in food are hydrolyzed in the intestinal lumen by phosphatases, releasing free riboflavin, which is transported into the enterocytes of the small intestine by an active, carrier-mediated process. This applies equally to supplemental FMN: riboflavin 5-phosphate is rapidly and almost completely dephosphorylated in the gastrointestinal lumen before absorption occurs.
The absorption and transportation of riboflavin is performed by a group of transporters from the solute carrier family SLC52. The majority of riboflavin is absorbed in the small intestine, but absorption also occurs in the stomach, duodenum, colon, and rectum, through an active carrier-mediated transport by riboflavin transporter 3 (RFVT3).
About 95% of riboflavin in the form of FAD or FMN from food is bioavailable up to a maximum of about 27 mg of riboflavin per meal or dose. The bioavailability of free riboflavin is similar to that of FAD and FMN. The transport process is saturable at about 30 mg in a single meal.
Flavokinase in the intestinal mucosa phosphorylates intracellular riboflavin, so that much of the riboflavin entering the plasma does so as FMN. Kinetic modeling following ingestion of stable isotope-labeled foods suggests that a large fraction of newly absorbed riboflavin is removed from the circulation on first-pass metabolism by the liver.
Riboflavin is carried in the plasma bound to albumin and to certain immunoglobulins, which can also bind FAD and FMN. Recent data show that about 70–75% of total riboflavin in the plasma is present as FAD, 5–10% as FMN, and 15–20% as free riboflavin.
FAD and FMN are widely distributed into body tissues, including gastrointestinal mucosal cells, erythrocytes, and the liver. Free riboflavin is present in the retina. Riboflavin is stored in limited amounts in the liver, spleen, kidneys, and heart, mainly in the form of FAD.
Excess riboflavin is excreted in urine and, since it is not a fat-soluble vitamin, is not stored in fat or other body tissues. Median plasma concentrations are approximately 10.5 nmol/L for riboflavin, 6.6 nmol/L for FMN, and 74 nmol/L for FAD. In erythrocytes, there were only trace amounts of riboflavin, whereas median FMN and FAD concentrations were 44 and 469 nmol/L, respectively.
The extent of gastrointestinal absorption of riboflavin is increased when the drug is administered with food and is decreased in patients with hepatitis, cirrhosis, biliary obstruction, or in those receiving probenecid.
Riboflavin, and more importantly its derivatives FMN and FAD, play a crucial role in essential cellular processes including mitochondrial energy metabolism, stress responses, vitamin and cofactor biogenesis, where they function as cofactors to ensure the catalytic activity and folding and stability of flavoenzymes. Signs of riboflavin deficiency are nonspecific and include sore throat, hyperaemia and oedema of the pharyngeal and oral mucous membranes, cheilosis, glossitis (magenta tongue), and normochromic normocytic anaemia characterised by erythroid hypoplasia and reticulocytopenia.
Importantly, 10–15% of the global population have an inherited condition of limited riboflavin absorption and utilization, leading to potential biochemical riboflavin deficiency worldwide. Based on erythrocyte glutathione reductase activation coefficient (EGRAC) testing, 54% of British non-elderly adult populations had at least borderline riboflavin deficiency. Riboflavin deficiency across European countries ranges between 7 and 20%.
Clinical research has investigated the relationships of EGRAC and plasma and erythrocyte concentrations of riboflavin, FMN, and FAD in elderly volunteers and their responses to riboflavin administration. In one study, EGRAC and plasma/erythrocyte concentrations of riboflavin, FMN, and FAD were determined in 124 healthy individuals with a mean age of 69 years. A subgroup of 46 individuals with EGRAC ≥1.20 participated in a randomized double-blind 12-week intervention study and received riboflavin (1.6 mg/day; n = 23) or placebo (n = 23). All variables except plasma FAD responded significantly to riboflavin supplementation compared with placebo. The strongest increases were for riboflavin in plasma (83%) and for FMN in erythrocytes (87%). Plasma riboflavin and erythrocyte FMN may be useful for the assessment of vitamin B2 status in population studies. This RCT is considered high-quality evidence supporting a clear dose-response relationship between riboflavin supplementation and the restoration of circulating FMN pools in deficient elderly individuals.
FMN's role at Complex I of the mitochondrial electron transport chain is one of the most firmly established facts in biochemistry and is supported by decades of mechanistic and structural research. NADH:ubiquinone oxidoreductase (complex I) is a complicated respiratory chain enzyme that conserves the energy from NADH oxidation, coupled to ubiquinone reduction, as a proton motive force across the mitochondrial inner membrane. This mechanistic understanding is not derived from clinical intervention trials but from direct biochemical and structural studies; it is treated as established science, not a clinical hypothesis.
A latent subclinical riboflavin deficiency can result in a significant clinical phenotype when combined with inborn genetic disturbances or environmental and physiological factors like infections, exercise, diet, aging, and pregnancy. Severe riboflavin deficiency can impair the metabolism of other nutrients, especially other B vitamins, through diminished levels of flavin coenzymes.
The flavoenzyme methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which serves as a methyl group donor in the conversion of homocysteine to methionine. In humans, reduced enzyme activity caused by the commonly occurring 677C→T substitution of the MTHFR gene is associated with elevated plasma homocysteine. The mutant enzyme has lower affinity for its flavin cofactor than the wild-type enzyme, and recent studies show that plasma homocysteine is inversely related to riboflavin in subjects with the T-allele.
Riboflavin is involved in maintaining normal circulating levels of homocysteine; in riboflavin deficiency, homocysteine levels increase, elevating the risk of cardiovascular diseases. The clinical evidence linking adequate FMN (via riboflavin status) to homocysteine reduction is strongest in individuals carrying the MTHFR 677TT genotype. Evidence is considered moderate in strength, primarily from observational cohorts and some intervention studies, rather than large-scale cardiovascular endpoint RCTs.
Riboflavin is one of the important components of oxidative metabolism due to its role as the precursor to coenzymes FMN and FAD in mitochondria. Therefore, riboflavin deficiency might be involved in the pathogenesis of migraine. The mechanistic hypothesis centers on mitochondrial energy dysfunction as a contributor to cortical spreading depression in migraine.
A randomized clinical trial demonstrated that high-dose riboflavin supplementation (400 mg/day) could decrease the attack frequency, duration, and severity of migraine. This RCT (Schoenen et al., 1998) is frequently cited in guidelines. Riboflavin supplementation has been evaluated as a prophylactic agent for migraine headache, but the results are conflicting. Most of the clinical evidence concerns riboflavin itself, not FMN specifically, since supplemental FMN is dephosphorylated to free riboflavin before absorption. The evidence for riboflavin in migraine prevention is rated as moderate, with guidelines typically recommending 400 mg/day. Evidence specific to FMN as a distinct supplemental entity in migraine is not available in the peer-reviewed literature; the biological activity is attributable to the riboflavin/FMN/FAD system collectively.
Riboflavin transporter deficiency (RTD) — historically termed Brown–Vialetto–Van Laere or Fazio-Londe syndrome — is a rare, early-onset motor neuron disease. Pathogenic loss-of-function variants in SLC52A2 or SLC52A3 abrogate membrane uptake of riboflavin, precipitating secondary FMN/FAD depletion in metabolically demanding neurons and glia. Consequent mitochondrial energy failure drives axonal degeneration, sensorineural deafness, and progressive bulbar weakness.
Mechanistic work in patient fibroblasts and iPSC-derived motor neurons confirms that transporter mutations collapse intracellular FMN/FAD pools, impair respiratory-chain flux and trigger neurite loss; high-dose riboflavin (≥10 mg/kg/day) or flavin esters rapidly restore ATP production and cell viability in vitro. In multicenter observational studies, RTD treated with 10–60 mg/kg/day (oral/IV) resulted in approximately 70–80% improvement or stabilization when treated early; this has been elevated to a Class I guideline recommendation.
Riboflavin supplementation — particularly in high doses — has demonstrated substantial efficacy in conditions such as riboflavin transporter deficiency (RTD), multiple acyl-CoA dehydrogenase deficiency (MADD), and migraine. For MADD, typical effective doses range from 20–60 mg/kg/day in children and 100–400 mg/day in adults, with rapid reversal of myopathy and metabolic crises observed in cohort studies and consensus statements. The evidence in MADD is rated moderate to strong for the riboflavin-responsive subgroup.
Flavin derivatives such as FAD and FMN are well known to regulate aerobic mitochondrial metabolism by mediating redox reactions through the electron transport chain, in particular at complex I–II (which are locations of injury associated with Parkinson's disease). Administration of riboflavin to humans can reverse clinical symptoms associated with mitochondrial myopathy/pathologies (involving complex I–II) as evidenced by a reduction in lactate, restored mitochondrial function, and clinical improvement. Current evidence in Parkinson's disease specifically is preliminary and limited; no large-scale clinical trials of FMN supplementation in PD have been completed as of the available literature.
Riboflavin deficiency appears to impair the metabolism of the dietary mineral iron, which is essential to the production of hemoglobin and red blood cells. Alleviating riboflavin deficiency in people who are deficient in both riboflavin and iron improves the effectiveness of iron supplementation for treating iron-deficiency anemia. The evidence here pertains to co-deficiency states rather than to a standalone therapeutic role for FMN in anaemia. Anaemia and cataracts can develop if riboflavin deficiency is severe and prolonged.
One observational clinical study focused on the influence of riboflavin (vitamin B2) supplementation on the immune markers of COVID-19 severity in patients with mental health disorders, and found that 10 mg of flavin mononucleotide intramuscularly twice a day within 7 days correlated with the normalization of clinically relevant immune markers (neutrophil and lymphocyte counts, as well as their ratio) in COVID-19 patients. This is a single observational study without a robust control arm, and the evidence is considered very preliminary. It should not be interpreted as establishing efficacy for FMN in treating COVID-19.
Non-toxic FMN, which is a water-soluble form of riboflavin (vitamin B2), has been proposed as a promising agent for photodynamic therapy of melanoma. Researchers demonstrated selective accumulation of FMN in melanoma cells in vivo and in vitro compared with keratinocytes and fibroblasts. Blue light irradiation with a dose of 5 J/cm² of melanoma cells pre-incubated with FMN led to cell death through apoptosis. The IC₅₀ values of human melanoma cells were in a range of FMN concentration of 10–30 µM. This represents an early-stage experimental application; there are no completed human clinical trials of systemic or topical FMN as a photodynamic agent.
Given FMN's universal role as a mitochondrial and flavoenzyme cofactor, it is associated with virtually every major organ system and metabolic pathway. The most firmly documented areas are summarized below:
FMN itself does not have an independently established Recommended Dietary Allowance (RDA). Recommendations are expressed in terms of riboflavin (vitamin B2), with FMN as the principal biologically active intracellular form. The Daily Value for riboflavin set by the U.S. FDA is 1.3 mg for adults and children age 4 years and older.
Recommended daily intakes in mg are as follows: babies (birth–6 months), 0.3 mg; infants (7–12 months), 0.4 mg; children (1–3 years), 0.5 mg; children (4–8 years), 0.6 mg; children (9–13 years), 0.9 mg; boys (14–18 years), 1.3 mg; girls (14–18 years), 1.0 mg; men (19 years plus), 1.3 mg; women (19 years plus), 1.1 mg; pregnant females, 1.4 mg; breastfeeding females, 1.6 mg.
Riboflavin is non-toxic and is used as a coloring agent in food and pharmaceuticals. The intake of riboflavin from food and dietary supplements ranges from 4 to 10 mg a day. No adverse effects have been associated with high intakes of riboflavin from food or supplements.
No tolerable upper intake level has been set for riboflavin. Human experience with riboflavin from food is extensive, and toxicology data consistently show very low systemic toxicity. Oral intake from the diet and typical supplements rarely causes clinically meaningful side effects, because absorption is regulated and excess riboflavin is excreted, often causing harmless bright-yellow urine.
At very high supplemental doses, some people report mild gastrointestinal discomfort. Bright yellow urine is common at higher intake and is harmless. True allergy to riboflavin preparations is uncommon.
Riboflavin is characterized by its unique bright yellow coloration of urine when taken in large amounts. This is a well-known, benign, and harmless pharmacodynamic effect that requires no clinical intervention.
The micronutrients riboflavin, FMN, and FAD are photo-sensitive to UV and visible light for generating reactive oxygen species (ROS). This photoreactivity is exploited in medical applications such as corneal cross-linking, where riboflavin/FMN acts as a photosensitizer. Under normal dietary or supplemental intake conditions, systemic phototoxicity is not a reported concern, though caution regarding light stability of FMN-containing products during manufacturing and storage is appropriate.
The extent of gastrointestinal absorption of riboflavin is increased when the drug is administered with food and is decreased in patients with hepatitis, cirrhosis, biliary obstruction, or in those receiving probenecid. Chronic alcohol consumption has been associated with riboflavin deficiency. In rats chronically fed alcohol, the inhibition of riboflavin transporters caused impairment in intestinal absorption and renal re-uptake of the vitamin.
The following interactions have been identified in the scientific and clinical literature. All are rated minor in severity:
While dietary supplementation with riboflavin is a recognized support therapy in several inborn errors of metabolism, it has yet unproven benefits in several other pathologies affecting flavoproteins. One example is glutaric aciduria type I (GA-I), a rare neurometabolic disorder associated with mutations in the GCDH gene, which encodes for glutaryl-coenzyme A dehydrogenase. In such conditions, clinically supervised assessment of FMN/FAD status and response to riboflavin loading is required.
Importantly, 10–15% of the global population have an inherited condition of limited riboflavin absorption and utilization, leading to a potential biochemical riboflavin deficiency worldwide. A latent subclinical riboflavin deficiency can result in a significant clinical phenotype when combined with inborn genetic disturbances or environmental and physiological factors like infections, exercise, diet, aging, and pregnancy.
Health conditions that Flavin mononucleotide may help support.
Severe or prolonged riboflavin (FMN/FAD) deficiency causes normocytic anemia by impairing iron absorption and hemoglobin synthesis. FMN deficiency disrupts the iron mobilization pathway. The NIH ODS confirms that anemia can develop with prolonged riboflavin deficiency and is reversible with supplementation.
FMN and FAD are essential for glutathione reductase, which regenerates the antioxidant glutathione, and for other flavoenzymes that protect cells from oxidative stress. Riboflavin deficiency depletes FMN/FAD and reduces antioxidant enzyme activity, increasing oxidative damage. This mechanism is well-established and documented across human biochemistry and clinical deficiency studies.
Multiple RCTs show that riboflavin supplementation (1.6 mg/day) lowers systolic blood pressure by 6-13 mmHg specifically in cardiovascular disease patients homozygous for the MTHFR 677TT genotype, independently of antihypertensive drugs. This effect is mediated through FAD/FMN stabilization of MTHFR, with downstream effects on homocysteine and nitric oxide signaling.
FMN is biochemically indispensable for ATP production as the electron-entry cofactor of mitochondrial Complex I, and also supports the citric acid cycle and fatty acid oxidation via FAD. StatPearls and multiple biochemistry reviews confirm that FMN/FAD depletion impairs cellular ATP production, and repletion studies demonstrate restoration of energy metabolism.
FMN supplementation has been shown in preclinical models to suppress amyloid-beta toxicity, modulate microglial neuroinflammation, and improve cognitive outcomes. Low riboflavin/FMN levels have been observed in dementia patients. Clinical evidence is preliminary but supports a mechanistic role for FMN in cognitive aging via antioxidant, anti-inflammatory, and homocysteine-lowering pathways.
FMN is the prosthetic group of mitochondrial Complex I (NADH dehydrogenase), where it accepts electrons from NADH and initiates the electron transport chain to drive ATP synthesis. Adequate FMN/FAD status is therefore biochemically essential for cellular energy production. Riboflavin deficiency, which depletes FMN, results in fatigue and impaired energy metabolism, reversible upon repletion.
FMN and FAD are obligate cofactors for methylenetetrahydrofolate reductase (MTHFR), the enzyme that converts homocysteine to methionine. Riboflavin (the FMN/FAD precursor) has been shown in randomized controlled trials to lower homocysteine specifically in individuals homozygous for the MTHFR 677C→T polymorphism. This effect is genotype-specific and not seen in wild-type individuals.
FMN and FAD are required cofactors for dozens of flavoenzymes involved in the metabolism of carbohydrates, fats, and proteins, including enzymes in the citric acid cycle, fatty acid beta-oxidation, and amino acid catabolism. Riboflavin deficiency, which depletes cellular FMN and FAD, leads to impaired fatty acid oxidation and mitochondrial dysfunction. Repletion studies confirm restoration of these metabolic functions.
FMN and FAD are obligate cofactors for MTHFR, the enzyme central to the one-carbon/methylation cycle that generates 5-methylTHF for homocysteine remethylation and downstream methylation reactions. Riboflavin supplementation stabilizes MTHFR activity specifically in 677TT carriers, supporting methylation flux. This is a well-characterized biochemical and clinical relationship.
Multiple RCTs and a 2025 dose-response meta-analysis of 12 trials (n=749) show that high-dose riboflavin (primarily 400 mg/day) significantly reduces migraine attack frequency and duration. The proposed mechanism involves FMN/FAD-dependent improvement of mitochondrial energy metabolism and reduction of oxidative stress in susceptible neurons.
FMN is the essential prosthetic group of mitochondrial Complex I and is required for normal mitochondrial respiratory chain function. Loss of FMN from Complex I occurs during ischemia-reperfusion injury and contributes to mitochondrial dysfunction. Riboflavin supplementation has been shown to restore mitochondrial function in patients with Complex I-related mitochondrial myopathy.
FMN and FAD are required for maintenance of myelin integrity and neuronal energy metabolism. Riboflavin transporter deficiency causes secondary FMN/FAD depletion and progressive motor neuropathy (Brown-Vialetto-Van Laere syndrome), which is treated with high-dose riboflavin. FMN deficiency from any cause can produce degeneration of the nervous system.
Body systems that Flavin mononucleotide may help support.
Go back